Cell injuryadaptation 2
•Télécharger en tant que PPT, PDF•
10 j'aime•1,318 vues
for Undergraduate medical students (MBBS)
Recommandé
Contenu connexe
Tendances
Tendances (20)
En vedette
En vedette (20)
Similaire à Cell injuryadaptation 2
Similaire à Cell injuryadaptation 2 (20)
Plus de Prasad CSBR
Dernier
Dernier (20)
Cell injuryadaptation 2
- 1. Cell Injury and Adaptations -2Cell Injury and Adaptations -2 Dr.CSBR.Prasad, M.D.
- 11. AtrophyAtrophy
- 12. Cell number Cell size Cell substance Organ / tissue size
- 13. AtrophyAtrophy Def: Shrinkage in the size of the cell by the loss of cell substance As a result organ / tissue size diminishes Ex: Skeletal muscle in disuse Ischemia causing reduction in size of a limb
- 14. AtrophyAtrophy Because of atrophy of cells, organ / tissue size diminishes Atrophic cells have diminished function but they are not dead There may be over all loss of number of cells in an organ It’s a retreat for the cells to a smaller size at which survival is still possible
- 15. AtrophyAtrophy Causes:Causes: 1. < work load 2. < blood supply 3. Inadequate nutrition 4. Loss of endocrine stimulation 5. Aging
- 16. AtrophyAtrophy Mechanism:Mechanism: Regulation of protein degradation play a key role in atrophy There are two proteolytic systemsThere are two proteolytic systems involved in degradationinvolved in degradation 1. Lysosomes 2. Ubiquitin-proteasome pathway
- 18. AtrophyAtrophy Microscopic changes:Microscopic changes: 1. Decrease in size of the cell 2. Marked increase in number of autophagic vacuoles 3. Lipofuchsin accumulation
- 31. AtrophyAtrophy
- 32. AtrophyAtrophy
- 33. Cancer cachexia:Cancer cachexia: Proteasome pathway is activated in hypercatabolic state including cancer cachexia
- 34. Lipofuscin granules in a cardiac myocyteLipofuscin granules in a cardiac myocyte
- 37. Cell number Cell size Cell substance Organ / tissue size
- 38. HypertrophyHypertrophy • Increase in size of the cells • Increase in organ size and tissue size • NO NEW CELLSNO NEW CELLS
- 39. HypertrophyHypertrophy Causes: • Increased functional demandIncreased functional demand • Specific hormonal stimulusSpecific hormonal stimulus
- 40. HypertrophyHypertrophy Basic Mechanisms: 1.1. Increased synthesis of structural proteinsIncreased synthesis of structural proteins / organelle/ organelle 2.2. Increased DNA contentIncreased DNA content 3.3. Rarely - a change in cellular phenotypeRarely - a change in cellular phenotype
- 41. Mechanisms of myocardial hypertrophy
- 43. HypertrophyHypertrophy Types:Types: 1-Physiological1-Physiological Eg:Eg: - Uterus during pregnancy- Uterus during pregnancy - Exercise induced increase in muscle bulk- Exercise induced increase in muscle bulk 2-Pathological2-Pathological Eg:Eg: - Concentric hypertrophy of LV in HTN / AS / AR- Concentric hypertrophy of LV in HTN / AS / AR - Hypertrophy of residual cardiac myocytes after MI- Hypertrophy of residual cardiac myocytes after MI - Hypertrophy of smooth muscle in the intestinal wall proximal- Hypertrophy of smooth muscle in the intestinal wall proximal to obstructionto obstruction Note:Note: some times hypertrophy and hyperplasia may occursome times hypertrophy and hyperplasia may occur togethertogether eg: uterus in pregnancyeg: uterus in pregnancy
- 44. HypertrophyHypertrophy Whatever the mechanism, after a stage,Whatever the mechanism, after a stage, degenerative changes take placedegenerative changes take place Eg: fragmentation and loss of myofilamentary contractile protein This may be due to increased demand for blood supply which is finite
- 50. Physiologic hypertrophy ofPhysiologic hypertrophy of the uterus during pregnancythe uterus during pregnancy
- 53. Cell number Cell size Cell substance Organ / tissue size
- 54. HyperplasiaHyperplasia • Increase in number of cells • Increase in organ size and tissue size • NEW CELLS will formNEW CELLS will form • New cell form from stem cells / resting cell
- 55. HyperplasiaHyperplasia Types:Types: • Physiological 1.1. HormonalHormonal eg: EM, Breast, Uterus in pregnancy 2.2. CompensatoryCompensatory eg: Partial hepatectomy, wound healing • Pathological EM hyperplasias, adrenal cortical hyperplasia due to pituitary tumor; TSH secreting adenoma of pituitary, Stimulatory Ig against TSH receptor---> thyroid hyperplasia; Androgens & prostate
- 56. HyperplasiaHyperplasia Pathological - Mostly due to excessive hormone stimulation or growth factor stimulation eg: EM proliferation - Increased sensitivity to growth factors eg: HPV infection of skin Note: pathological hyperplasias constitute a fertile soil for possible future cancer Eg: EM hyperplasia HPV infection and cervical cancer
- 57. HyperplasiaHyperplasia Main difference between hyperplasia andMain difference between hyperplasia and cancers:cancers: In Hyperplasia : proliferation is controlled In Cancers : proliferation is uncontrolled
- 59. 1 - In a patient with bleeding PV, US1 - In a patient with bleeding PV, US showed endometrial hyperplasia.showed endometrial hyperplasia. • What do you elicit in history? • Assume that this patient had an ovarian tumor. Can you guess what is the nature of tumor? Collaterals: • What do you call such tumors? Can you give some more examples? • Unfortunately, endometrial biopsy turned out to be endometrial carcinoma. Surgeon considered oophorectomy as a part of treatment. What is your comment?
- 60. 2 - Earlier breast carcinomas were2 - Earlier breast carcinomas were treated by mastectomy andtreated by mastectomy and oophorectomy and adrenalectomy.oophorectomy and adrenalectomy. • How oophorectomy will benefit the patient?
- 62. MetaplasiaMetaplasia Def: one adult cell type is replaced by another adult cell type It’s a reversiblereversible change It may involve epitheliumepithelium or mesenchymalmesenchymal tissue
- 63. MetaplasiaMetaplasia Preference to the fittest for a given injury
- 64. MetaplasiaMetaplasia Mechanism:Mechanism: Arises from genetic reprogramming of epithelial stem cells or of undifferentiated mesenchymal cells
- 65. MetaplasiaMetaplasia Examples:Examples: Smoking : squamous metaplasia of respiratory epithelium Vit-A deficiency: squamous metaplasia of respiratory epithelium Chronic cervical infections: squamous metaplasia of endocervical epithelium Urinary stones: squamous metaplasia of urothelium GERD: gatric / intestinal metaplasia in squamous epithelium of esophagus Gastritis: Mucous metaplasia in gastric epithelium
- 66. MetaplasiaMetaplasia Also occur in mesenchymal tissue BUT - It’s not an adaptive response Examples:Examples: - bone & cartilage formation in soft tissues after an injury - tumor metaplasias
- 67. MetaplasiaMetaplasia Consequences:Consequences: 1. Loss of protective mechanism 2. Fertile soil for cancers
- 72. Metaplasia in esophagusMetaplasia in esophagus
- 76. Intracellular accumulationsIntracellular accumulations Accumulation of abnormal amounts of various substances Three categories:Three categories: 1- Normal cellular constituents accumulated in excess eg: H2O, Lipid, Proteins, CHO 2- Accumulation of abnormal substance Exogenous eg: minerals, infectious agents Endogenous eg: abnormal synthesis, abnormal metabolism 3- Pigment
- 77. Intracellular accumulationsIntracellular accumulations Substances accumulated:Substances accumulated: 1. Transient accumulations 2. Permanent accumulations • Harmless • Toxic 1. Cytoplasm 2. Nucleus
- 78. Intracellular accumulationsIntracellular accumulations Processes that result in intracellular accumulations:Processes that result in intracellular accumulations: 1. Normal endogenous product at the normal rate / induced rate but with reduced rate of removal 2. Normal / abnormal endogenous products accumulate bec’ of defective metabolism (packge/transport/secretion). It’s usually a gentic defect 3. Accumulation of abnormal exogenous substance bec’ cell has no machinary to degrade or export to other sites
- 79. Intracellular accumulationsIntracellular accumulations If Overload is due toIf Overload is due to: Systemic derangementsSystemic derangements: reversible Genetic defectGenetic defect: irreversible - progressive
- 80. Intracellular accumulationsIntracellular accumulations Accumulation of LIPIDSAccumulation of LIPIDS: Any class of lipids may get accumulatedAny class of lipids may get accumulated TriglyceridesTriglycerides Cholesterol / cholesterol esterCholesterol / cholesterol ester PhospholipidsPhospholipids Complex of lipids & carbohydratesComplex of lipids & carbohydrates (Eg: Lysosomal storage diseases)(Eg: Lysosomal storage diseases)
- 81. Intracellular accumulationsIntracellular accumulations FATTY CHANGE: (STEATOSIS)FATTY CHANGE: (STEATOSIS) Accumulation of triglyceridesAccumulation of triglycerides Usually seen inUsually seen in liverliver (can also occur in kidney, heart, skeletal(can also occur in kidney, heart, skeletal muscle)muscle)
- 82. Intracellular accumulationsIntracellular accumulations FATTY CHANGE: (STEATOSIS)FATTY CHANGE: (STEATOSIS) Causes:Causes: ToxinsToxins AlcoholAlcohol PEMPEM DMDM ObesityObesity AnoxiaAnoxia
- 84. Intracellular accumulationsIntracellular accumulations FATTY CHANGE:FATTY CHANGE: LiverLiver Significance:Significance: depends on thedepends on the CauseCause Severity of accumulationSeverity of accumulation NASHNASH (may lead to cirrhosis, HCC)(may lead to cirrhosis, HCC)
- 85. Intracellular accumulationsIntracellular accumulations FATTY CHANGE:FATTY CHANGE: LiverLiver Morphology:Morphology: Uniform enlargementUniform enlargement Yellowish with greater accumulation of fatYellowish with greater accumulation of fat Borders are sharpBorders are sharp Capsule is stretchedCapsule is stretched c/s greasyc/s greasy
- 86. Intracellular accumulationsIntracellular accumulations FATTY CHANGE:FATTY CHANGE: LiverLiver Microscopy:Microscopy: Minute membrane bound vesiclesMinute membrane bound vesicles First seen around the nucleusFirst seen around the nucleus With progressive accumulation cellsWith progressive accumulation cells resembles adipocyteresembles adipocyte Fatty cystsFatty cysts
- 88. Intracellular accumulationsIntracellular accumulations FATTY CHANGE:FATTY CHANGE: HeartHeart Gross:Gross: Two patterns of accumulationsTwo patterns of accumulations Tigroid effect (hypoxia)Tigroid effect (hypoxia) alternating layers of brown and yellowalternating layers of brown and yellow Yellow heart (Diphtheria, severe hypoxia)Yellow heart (Diphtheria, severe hypoxia) Diffuse accumulation in almost all cellsDiffuse accumulation in almost all cells
- 90. Intracellular accumulationsIntracellular accumulations FATTY CHANGE:FATTY CHANGE: HeartHeart Microscopy:Microscopy: Small clear vaucoles in the cardiacSmall clear vaucoles in the cardiac myocytesmyocytes
- 93. Intracellular accumulationsIntracellular accumulations FATTY CHANGE:FATTY CHANGE: DDDD Intracellular accumulations ofIntracellular accumulations of fatfat,, glycogenglycogen andand waterwater cannot be differentiated bycannot be differentiated by routine histologyroutine histology Special stains are needed forSpecial stains are needed for differentiationdifferentiation
- 94. Intracellular accumulationsIntracellular accumulations FATTY CHANGE:FATTY CHANGE: DDDD Special stains that will help to differentiate fat andSpecial stains that will help to differentiate fat and glycogenglycogen Sudan III / IVSudan III / IV fat – red / orangefat – red / orange Sudan blackSudan black fat – blackfat – black Oil Red – OOil Red – O fat – red / orangefat – red / orange Nile blue ANile blue A fat – redfat – red PASPAS stains glycogen (pink)stains glycogen (pink) NoteNote:: for the demonstration of fatfor the demonstration of fat frozen sections are used.frozen sections are used.
- 96. Atherosclerosis, Oil red - O
- 97. Intracellular accumulationsIntracellular accumulations Cholesterol / cholestryl ester:Cholesterol / cholestryl ester: Every cell uses choleterol for the synthesis of itsEvery cell uses choleterol for the synthesis of its cell membranecell membrane Accumulation of cholesterol is alwaysAccumulation of cholesterol is always pathologicalpathological Conditions:Conditions: CholesterolosisCholesterolosis ASAS XanthomasXanthomas Inflammation / necrosisInflammation / necrosis Niemann – Pick disease type-CNiemann – Pick disease type-C
- 98. Intracellular accumulationsIntracellular accumulations Atherosclerosis:Atherosclerosis: Seen in large and medium sized arteriesSeen in large and medium sized arteries MØ smooth muscle cells accumulate withMØ smooth muscle cells accumulate with in the intimal layerin the intimal layer They are filled with lipid vacuoles – FoamThey are filled with lipid vacuoles – Foam cellscells GrossGross: produces yellow plaques: produces yellow plaques Cholesterol clefts may be seenCholesterol clefts may be seen
- 99. Fatty streaks
- 100. Fatty streaks
- 101. Varying grades of AS
- 102. AS involving coronary artery – cholesterol clefts
- 103. AS involving coronary artery – Foamy macrophages, cholesterol clefts
- 104. Cholesterol clefts
- 105. Intracellular accumulationsIntracellular accumulations Xanthomas:Xanthomas: Intracellular accumulation of fat in MØIntracellular accumulation of fat in MØ Some hereditary hyperlipidemiasSome hereditary hyperlipidemias Foam cells are seen in the subepithelialFoam cells are seen in the subepithelial connective tissueconnective tissue Clinically they produce tumorsClinically they produce tumors
- 106. Intracellular accumulationsIntracellular accumulations Inflammation / necrosis:Inflammation / necrosis: foamy MØ are seen at these sitesfoamy MØ are seen at these sites When they are in excessive number theyWhen they are in excessive number they produce yellowish colour to the siteproduce yellowish colour to the site Eg:Eg: Xanthogranulomatous pyelonphritisXanthogranulomatous pyelonphritis xanthogranulomasxanthogranulomas
- 108. Intracellular accumulationsIntracellular accumulations Cholesterolosis:Cholesterolosis: Focal accumulations of foamy MØ in theFocal accumulations of foamy MØ in the lamina propria of gall bladderlamina propria of gall bladder
- 112. Tendinous xanthomas
- 113. Erruptive xanthomas
- 114. Xanthelasma
- 116. Niemann-Pick Disease
- 117. Niemann-Pick Disease
- 120. E N D
Notes de l'éditeur
- Cell number – remain sameCell size - DecreasedCell substance - DeceasedOrgan / tissue size - Deceased
- It’s a retreat for the cells to a smaller size at which survival is still possible. A new equilibrium is achieved between size and diminished blood supply / nutrition / trophic stimulation.
- Decreased synthesis and increased catabolism or both may cause atrophy. Synthesis and degradation of cellular constituents are influenced by hormones like: insulin, TSH, glucocorticoids.
- Lysosomes: Contain proteases and other enzymes that degrade molecules endocytosed from the extracellular environment as well as catabolize subcellular components such as Senescent organelle. Ubiquitin-proteasome pathway: Many cytosolic and nuclear proteins are degraded in this fashion. First the protein to be degraded is bound to Ubiquitin. Then it enters ‘Proteasome’, a cytoplasmic proteolytic complex, where it’s degraded. (this pathway is responsible for the accelerated proteolysis in hypercatabolic states ex: cancer cachexia and for regulation of intracellular activation molecules).
- Autophagic vacuole: a fusion of lysosomes with intracellular organelle and cytosol that allows the catabolism and turnover of self-components in a given cell. Lipofuschsin: Some of the cell debris within the autophagic vacuole may resist digestion and persist as membrane bound residual bodies.
- There are some muscle fibers here that show atrophy. The number of cells is the same as before the atrophy occurred, but the size of some fibers is reduced. This is a response to injury by &quot;downsizing&quot; to conserve the cell. In this case, innervation of the small fibers in the center was lost. This is a trichrome stain.
- The testis at the right has undergone atrophy and is much smaller than the normal testis at the left.
- FIGURE 1-33 Lipofuscin granules in a cardiac myocyte shown by (A) light microscopy (deposits indicated by arrows), and (B) electron microscopy (note the perinuclear, intralysosomal location).
- Cell number – remain sameCell size - IncreasedCell substance - IncreasedOrgan / tissue size - Increased
- Increased functional demand : Skeletal muscle hypertrophy in athletes, ER hypertrophy in liver cells with long term phenytoin consumption, Nesidioblastosis. Specific hormonal stimulus: Increased ACTH secretion and Adrenal cortical hyperplasia, Increased TSH secretion and hyperplastic goitre.
- Increased synthesis of structural proteins / organelle: Many of the cells in adults are fixed cells, unable to divide. Hence to meet the demand there is increased synthesis of proteins and myofilaments (in skeletal muscle) satisfies the demand for increased activity. It permits an increased work load with a a level of metabolic activity per unit volume of cell not different from that borne by the normal cell. Change in cellular phenotype: in cardiac volume overload some genes which are normally active in neonatal heart are reactivated. Hence contractile protein switched to fetal isoform which contracts slowly.
- FIGURE 1-4 Biochemical mechanisms of myocardial hypertrophy. The major known signaling pathways and their functional effects are shown. Mechanical sensors appear to be the major triggers for physiologic hypertrophy, and agonists and growth factors may be more important in pathologic states. ANF, atrial natriuretic factor; IGF-1, insulin-like growth factor.
- Increased synthesis of structural proteins / organelle: Many of the cells in adults are fixed cells, unable to divide. Hence to meet the demand there is increased synthesis of proteins and myofilaments (in skeletal muscle) satisfies the demand for increased activity. It permits an increased work load with a a level of metabolic activity per unit volume of cell not different from that borne by the normal cell. Change in cellular phenotype: in cardiac volume overload some genes whixh are normally active in neonatal heart are reactivated. Hence contractile protein switched to fetal isoform which contracts slowly.
- This is cardiac hypertrophy involving the left ventricle. The number of myocardial fibers does not increase, but their size can increase in response to an increased workload, leading to the marked thickening of the left ventricle in this patient with systemic hypertension.
- FIGURE 1-3 Physiologic hypertrophy of the uterus during pregnancy. A, Gross appearance of a normal uterus (right) and a gravid uterus (removed for postpartum bleeding) (left). B, Small spindle-shaped uterine smooth muscle cells from a normal uterus, compared with C, large plump cells from the gravid uterus, at the same magnification.
- In wound healing there will be proliferation of fibroblasts and endothelial cells.
- In wound healing there will be proliferation of fibroblasts and endothelial cells. HPV infection: type-6 & 11: low risk for cervical cancer; types-16 & 18 high risk for cervical cancer.
- In wound healing there will be proliferation of fibroblasts and endothelial cells.
- FIGURE 1-3 Physiologic hypertrophy of the uterus during pregnancy. A, Gross appearance of a normal uterus (right) and a gravid uterus (removed for postpartum bleeding) (left). B, Small spindle-shaped uterine smooth muscle cells from a normal uterus, compared with C, large plump cells from the gravid uterus, at the same magnification.
- -- What you elicit in history? (Hormonal intake ex: HRT) -- Assume that this patient had an ovarian tumor. Can you guess what is the nature of tumor? (Granulosa cell tumor) -- What do you call such tumors? Can you give some more examples? (Functional tumors, Insulinoma, glucagonoma, VIPoma, Acromegaly) -- Unfortunately, endometrial biopsy turned out to be endometrial carcinoma. Surgeon considered oophorectomy as a part of treatment. What is your comment? (Endometrial carcinomas are estrogen dependent, hence surgeon wanted to remove the source of stimulus)
- How oophorectomy will benefit the patient? (Removal of source for estrogen)
- In wound healing there will be proliferation of fibroblasts and endothelial cells.
- Gastric epithelium for stratified squamous epithelium. Squmous for columnar in cervix. Squamous for transitional in bladder. Squamous for ciliated columnar in respiratory system.
- Mesenchymal metaplasia: Synovial chondromatosis, Myositis ossificans.
- Loss of protective mechanism: although adaptive metaplastic wpithelium has survival advantage, important protective mechanisms are lost. Ex: mucus secretion, ciliary action in the case respiratory epithelium. Fertile soil for cancers: insults that induce metaplastic transformation if persist may induce cancer.
- Squamous metaplasia in cervix.
- Metaplasia of esophageal squamous mucosa has occurred here, with gastric type columnar mucosa at the left.
- This is dysplasia. The normal squamous epithelium at the left transforms to a disorderly growth pattern at the right. This is farther down the road toward neoplasia.
- Examples: 1- fatty change in liver; protein resorbtion by renal tubular epithelium in NS 2- storage disorder (lipid / carbohydrate); A1AT deificiency (A1AT enzyme because of it has abnormal structure which prevents it ti form foldings-hence it’s useless and get accumulated) 3- accumulation of carbon particles, silica particles.
- Examples: 1- fatty change in liver; protein resorbtion by renal tubular epithelium in NS 2- storage disorder (lipid / carbohydrate); A1AT deificiency (A1AT enzyme because of it has abnormal structure which prevents it ti form foldings-hence it’s useless and get accumulated) 3- accumulation of carbon particles, silica particles.
- Accumulation of LIPIDS: Any class of lipids may get accumulated Triglycerides Cholesterol / cholesterol ester Phospholipids Complex of lipids & carbohydrates (lysosomal storage diseases)
- Examples: 1- fatty change in liver; protein resorbtion by renal tubular epithelium in NS 2- storage disorder (lipid / carbohydrate); A1AT deificiency (A1AT enzyme because of it has abnormal structure which prevents it ti form foldings-hence it’s useless and get accumulated) 3- accumulation of carbon particles, silica particles. 4-fatty change in heart in diphtheria / ischemic injury.
- Examples: 1- fatty change in liver; protein resorbtion by renal tubular epithelium in NS 2- storage disorder (lipid / carbohydrate); A1AT deificiency (A1AT enzyme because of it has abnormal structure which prevents it ti form foldings-hence it’s useless and get accumulated) 3- accumulation of carbon particles, silica particles.
- With progressive accumulation vacuoles coalesce to form a single large vacuole with peripherally pushed nucleus (resembles adipocyte). Some times neighbouring cells rupture to produce cystic spaces fiolled with lipid – fatty cysts.
- Oil Red O & Sudan Black: Lipids in tissues present something of a challenge to histologists and pathologists. Lipids are relatively unreactive, chemically speaking. Even unsaturated lipids have few available sites to which stain molecules can bind. We&apos;ve seen that osmium tetroxide will covalently add to lipids, but OsO4 is pretty nasty stuff to handle and it&apos;s extremely expensive. As a routine light microscopic stain for lipids it has little real practical application. Another problem is that lipids don&apos;t remain in the tissues in routine processing: they get leached out by the numerous solvents used in preparing the typical wax sections for staining (i.e., xylene and alcohol). Hence, by the time the stains get applied, the presence of lipids is inferred by their absence in the section: large areas without any staining and without, in fact, any tissue at all. This isn&apos;t a problem in plastic-embedded tissues, which are processed without the prolonged solvent immersions needed for wax; but 99% of all clinical labs still use wax embedment because of its low cost, its suitability to automatic tissue processors, and the long-established and well-tested staining routines that they use. Plastic sections are superior in definition and detail, but wax is faster and cheaper, and for diagnostic purposes, almost as good. Most lipid &quot;stains&quot; aren&apos;t truly stains at all. They don&apos;t form covalent bonds with lipid components, and they can&apos;t for ionic bonds or hydrogen bonds, either. Instead, lipid &quot;stains&quot; depend on preferential solubility of some chemicals. Twp examples are Oil Red O and Sudan Black. Both of these use preferential partitioning into the lipid compartment to achieve their results.
- Arch Dis Child 1999;81:483-486 doi:10.1136/adc.81.6.483 Original article Xanthogranulomatous pyelonephritis in childhood F M J Quinna, A C Dicka, M T Corballya, M B McDermottb, E J Guineya + Author Affiliations aDepartment of Surgery, Our Lady&apos;s Hospital for Sick Children, Crumlin, Dublin 12, Republic of Ireland, bDepartment of Pathology, Our Lady&apos;s Hospital for Sick Children Dr Quinn. Accepted 25 June 1999 Abstract BACKGROUND Xanthogranulomatous pyelonephritis is a severe, atypical form of chronic renal parenchymal infection accounting for 6/1000 surgically proved cases of chronic pyelonephritis. Its manifestations mimic those of neoplastic and other inflammatory renal parenchymal diseases and, consequently, it is often misdiagnosed preoperatively. AIM To examine the relation between clinical history and the results of renal investigations performed in children with xanthogranulomatous pyelonephritis. METHOD A retrospective review of 31 cases presenting with the histopathological diagnosis of xanthogranulomatous pyelonephritis between 1963 and 1999. RESULTS The mean follow up was 8.2 years. The male:female ratio was 1:1.1. The left kidney was affected in 26 of the 31 patients. The positive findings on examination and investigation at presentation were: fever, 16 children; pyuria, 26 children; positive urine culture, 16 children. A haemoglobin of &lt; 100 g/l was measured in 27 of 31 patients and 15 of 18 patients tested had a raised erythrocyte sedimentation rate of &gt; 20 mm in the first hour. Twenty six children had renal calculi, with a large reduction in the function of the affected kidney on isotope scintigraphy in 27 of the 29 patients tested. Hypertrophy of the contralateral kidney, shown on imaging, was present in 17 of 31 patients. CONCLUSIONS Increasing awareness of this condition should lead to the diagnosis being suspected preoperatively.
- Cholesterolosis of Gall Bladder •Gallbladder has been opened displaying the mucosa •Innumerable tiny (1mm or less) bright yellow dots represent foci of cholesterol filled macrophages in the mucosa •No stones are present in this case although it is common to find evidence of chronic cholecystitis and cholelithiasis in these cases (Description By:Melinda Sanders,M.D. ) (Image Contrib. by:Melinda Sanders,M.D. UCHC )
- Familial hypercholesterolemia.
- Hypertriglyceridemia.
- Xanthelasma: Xanthelasma (or xanthelasma palpebrarum) is a sharply demarcated yellowish collection of cholesterol underneath the skin, usually on or around the eyelids. Although not harmful or painful, these minor growths may be disfiguring and can be removed. The plural is &quot;xanthelasmata&quot;. They are common in people of Asian origin and those from the Mediterranean region. Xanthelasmata can be removed with trichloroacetic acid peel, surgery, lasers or cryotherapy. Removal can cause scarring and pigment changes, but it is unusual after treatment with trichloroacetic acid. Because of the hereditary component, they may or may not indicate high blood levels of cholesterol. Where there is no family history of xanthelasmata they usually indicate high cholesterol and may correlate with a risk of atheromatous disease (cholesterol building up in arteries). The root of the word is from Greek xanthos,&quot;yellow&quot;.
- MPS I is a progressive, multi-systemic disease and presenting features vary depending on disease severity. Early diagnosis is critical. However, the earliest signs may be common in non-affected children and infants, which may complicate diagnosis. Still, the signs and symptoms below may lead to clinical suspicion of MPS I and warrant more definitive testing. Because the disease affects many organ systems, diagnosis may require collaboration with several specialists. Coarse features On the severe end of the disease spectrum, patients may have coarse facial features that develop slowly in the first year. By 2 years of age coarse features may be fairly obvious. This coarseness, which leads to the loss of fine detail in the infant’s facial features, is caused by storage of glycosaminoglycans (GAGs) in the orofacial region, as well as by underlying facial bone dysostosis. Thickened nostrils, lips, and ear lobules and enlargement of the tongue are all characteristics that become progressively more evident. Facial and body hypertrichosis is often seen by 24 months of age, at which time the facial and scalp hair may be coarse, straight and thatch-like. The appearance of individuals with attenuated MPS I is extremely variable. They may have short stiff necks, broad mouths, square jaws and receding chins (micrognathia). Some with less severe MPS I can have almost normal appearance. Developmental delay Patients with MPS I manifest a wide range of intellectual involvement. MPS I patients will suffer progressive and profound mental retardation, while patients on the attenuated end of the disease spectrum will exhibit little or no intellectual dysfunction.[6] In severe patients historically known as Hurler patients, early development may be normal but developmental delay is usually suspected by 12 months.[6] Thereafter, there is usually progressive deterioration, and by 18 months, developmental delay is usually apparent. From this point on, patients generally do not progress in development but plateau for a number of years followed by a slow decline in intellectual capabilities. Gibbus deformity Gibbus deformity refers to a bump in the lower back due to an abnormal curvature of the spine. This forward bend, or thoracolumbar kyphosis, in the lower spine occurs in about 90% of children with severe MPS I. It develops from poor bone growth in the upper front part of the vertebrae, which results in a wedging of the vertebrae. Occasionally, children may suffer from both kyphosis and scoliosis, making surgical intervention more likely and more complex. Gibbus deformity is usually observed within 10-14 months. Hepatosplenomegaly In severe patients and attenuated patients with moderate-to-severe symptoms, glycosaminoglycan (GAG) accumulation causes enlargement of both the liver and spleen (hepatosplenomegaly). The liver may also be enlarged in less severely affected individuals. The large liver does not usually cause liver problems, but it can interfere with eating and breathing. Joint restriction Joint manifestations are among the most significant disability and discomfort for patients with MPS I.[2] Almost all patients experience progressive arthropathy affecting all joints, and eventually leading to the loss of (or severe restriction of) range of motion. This can be the first disease manifestation to be noticed in MPS I patients Macrocephaly Children with severe MPS I generally have large heads, in part a consequence of the thickened calvaria that also produces a characteristic cranial appearance.[2] The head tends to be longer than normal from front to back (scaphocephaly) and the forehead is often particularly prominent, or prow-shaped, as a consequence of cranio-synostosis. Thickened nostrils, lips, and ear lobules and enlargement of the tongue are all characteristics that become progressively more evident. Recurrent infections In patients on the severe end of the disease spectrum, glycosaminoglycan (GAG) storage within the oro-pharynx with associated enlargement of the tongue, tonsils, and adenoids can lead to significant upper airway complications.[6] Lung volumes are often reduced because of the small thorax and hepatosplenomegaly limiting excursion of the diaphragm. Recurrent respiratory infections are common, and respiratory insufficiency is a major cause of mortality. Mildly affected patients with attenuated disease may not be affected by ear, nose, throat, and chest problems. Otitis Media What is otitis media? Otitis media (OM) is an infection or inflammation of the middle ear. This inflammation often begins when infections that cause sore throats, colds, or other respiratory or breathing problems spread to the middle ear. In MPS I, OM is caused, in part, by the buildup of glycosaminoglycans (GAGs) in the middle ear, nose, mouth, and throat. Acute Otitis Media Acute OM occurs when fluid is present in the middle ear, along with signs or symptoms of ear infection such as bulging eardrum often with pain, ear tugging, fever, irritability, decreased appetite, vomiting, and diarrhea. OM with effusion occurs when fluid is present without signs of infection. Although rare, complications can include tympanic membrane perforation, acute mastoiditis, cholesteatoma, meningitis, and epidural abscess.[1] Some degree of deafness is common for both severe and attenuated patients, and can be made worse by frequent ear infections. Mildly affected individuals with attenuated MPS I may be unaffected by ear, nose, throat, and chest problems. Recurrent Otitis Media Recurrent otitis media, infection of the middle ear, is one of the more stubborn problems for children with severe MPS I and to a lesser extent, individuals with attenuated MPS I who have moderate-to-severe symptoms.[1] Recurrent OM is caused, in part, by the buildup of GAGs in the middle ear, nose, mouth, and throat.
- Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), Types A and B: Etiology and Pathogenesis[1,2,3] Acid sphingomyelinase breaks down a lipid called sphingomyelin. With both types A and B, the enzyme is deficient, with the more severe deficiency associated with the A phenotype. Sphingomyelin and cholesterol accumulate in lysosomes to form fatty deposits with a foamy, swollen appearance. Acid sphingomyelinase (ASM) deficiency is distinguished clinically from Niemann-Pick type C (which results from cholesterol transport defects) by the following: Absence of vertical supranuclear ophthalmoplegia in type C Early and rapid neurological decline in neuronopathic ASM deficiency Apparent lack of progression or total absence of neurologic symptoms in non-neuronopathic ASM deficiency Clinical Description[3,4] Patients with acid sphingomyelinase (ASM) deficiency show evidence of fatty deposits in one or more organs. Those with neuronopathic ASM deficiency generally present within the first few months and were historically classified as having Niemann-Pick disease type A. Patients with non-neuronopathic ASM deficiency can present at any age and were historically classified as having Niemann-Pick disease type B. However, these clinical descriptions represent the extremes of a heterogeneous disease continuum and should not be used to predict disease course. In patients with partial enzyme deficiencies, the accumulation of sphingomyelin and Niemann-Pick cells leads to hepatosplenomegaly, pulmonary infiltration and insufficiency, significant growth and pubertal delay, and elevated tissue cholesterol levels. The age and cause of death are variable. More severe enzyme deficiencies also lead to clinically significant accumulation of sphingomyelin in the brain with progressive neurological impairment and death, usually by age 3. Inheritance pattern: autosomal recessive Incidence: pan-ethnic, type A higher frequency among Ashkenazi Jews[5]; 1 in 248,000 live births[5] Diagnosis: enzyme assay Conditions with similar presentations: Gaucher disease; GM1 Gangliodosis Management: no disease-specific treatment available; clinical trials for enzyme replacement therapy under investigation Other medical care:[2] symptom management
- Wegener’s granulomatosis: “The name adds insult to injury,” a patient with the condition says. A Nazi Past Casts a Pall on Name of a Disease By BARNABY J. FEDER Published: January 22, 2008, New York Times. What’s in a disease’s name? Long-hidden shame, perhaps. In most cases, as with lung cancer or heart failure, names are not much more than thumbnail descriptions. But for a few common illnesses like Alzheimer’s disease and for hundreds of rarer ones, doctors and patients often use names honoring the first doctor to publicize the illness or its symptoms. Some doctors have criticized that as a source of confusion. Different names are used in different countries in some cases. And because some names became widely used before the disease was fully understood, the names may obscure ties to related problems. What’s in a disease’s name? Long-hidden shame, perhaps. Skip to next paragraph Enlarge This Image James Cavallini/Photo Researchers Wegener’s granulomatosis. “The name adds insult to injury,” a patient with the condition says. Related Times Health Guide: Wegener’s granulomatosis Web Links An Editorial in a Medical Journal With Links to Other Sources on the Issue of Diseases Named After Doctors National Institutes of Health on Wegener&apos;s disease Non-profit Clearinghouse for Information on Wegener&apos;s and Related Diseases In most cases, as with lung cancer or heart failure, names are not much more than thumbnail descriptions. But for a few common illnesses like Alzheimer’s disease and for hundreds of rarer ones, doctors and patients often use names honoring the first doctor to publicize the illness or its symptoms. Some doctors have criticized that as a source of confusion. Different names are used in different countries in some cases. And because some names became widely used before the disease was fully understood, the names may obscure ties to related problems. Another shortcoming is drawing new attention. The controversy centers on Dr. Friedrich Wegener, a German pathologist who in 1936 identified a rare blood vessel inflammation that since the 1950s has been called Wegener’s granulomatosis. The American College of Chest Physicians awarded Wegener a “master clinician” prize in 1989, a year before he died. In 2000, Dr. Eric Matteson, a rheumatologist at the Mayo Clinic, and Dr. Alexander Woywodt, a kidney specialist now living in England, set out to write a column celebrating Wegener for The Lancet, the British medical journal. They uncovered a Nazi past that Wegener had kept secret after World War II. Unlike doctors who joined the Nazi Party to be allowed to practice, Wegener joined the movement in 1932, before Hitler took power. He rose to a relatively high military rank and spent some of the war in a medical office three blocks from the Jewish ghetto in Lodz, Poland. Sketchy records suggest that he might have participated in experiments on concentration camp inmates. “I can’t directly link him to a specific experiment,” Dr. Matteson said. Records show that other members of the Lodz health office did such research and that Wegener autopsied a prisoner with oxygen injected in his bloodstream in an embolism study. “He was a true believer, and it’s inconceivable that he didn’t know about what was going on there,” Dr. Matteson said. Wegener’s granulomatosis can be fatal without continuous drug therapy. Because it is often mistaken for more common diseases, patients feel grateful when doctors finally identify it, said Dianne G. Shaw of Chapel Hill, N.C., who received a diagnosis of the disorder in 1995. But she said she and many others were distressed to learn of the name’s Nazi associations. “The name adds insult to injury,” said Ms. Shaw, who prefers calling her condition vasculitis, the broader term for the family of diseases that includes Wegener’s. The case recalls that of Dr. Hans Conrad Reiter, a senior Nazi official who left a much clearer trail of war crimes. In the early 1940s, Reiter’s name became linked to a form of arthritis that he had written about decades earlier. His war record was publicized in the 1990s. Although many doctors still refer to Reiter’s syndrome, some journals and textbooks now call it reactive arthritis. The movement to discredit the Wegener name is beginning to gather momentum. The chest physicians’ group has rescinded its prize. Dr. Matteson and others, including some of the tens of thousands of American patients with Wegener’s granulomatosis, seek a more descriptive term. At the moment, the most precise candidate is ANCA-associated granulomatous vasculitis, which does not exactly trip off the tongue. ========================== Friedrich Wegener (1907-1990) was a German pathologist who is notable for his description of a rare disease. Although this disease was known before Wegener&apos;s description, since the 1950s it has been called by the name Wegener’s granulomatosis.Wegener joined the Nazi Party in 1932. As a relatively high ranking military doctor he spent some of the war in a medical office three blocks from the Lodz Ghetto, a Jewish ghetto in Lodz, Poland. There is speculation that he participated in experiments on concentration camp inmates.The American College of Chest Physicians (ACCP) awarded Wegener a “master clinician” prize in 1989. After his Nazi past was discovered in 2000, the ACCP rescinded the prize and, separately, a campaign was begun to rename Wegener’s granulomatosis to ANCA-associated granulomatous vasculitis. READ MORE: http://www.nytimes.com/2008/01/22/health/22dise.htmlhttp://www.chestjournal.org/content/132/6/2065.full.pdf+html HEINRICH RUDOLF HERTZ AND WEGENER&apos;S GRANULOMATOSIS: The hertz standard unit was named in honor of Heinrich R. Hertz, a German physicist who was a pioneer in the study of electromagnetic radiation.Heinrich Hertz is credited with the discovery of electromagnetic waves. Hertz performed numerous experiments and provided a wealth of data concerning reflection, refraction, and interference with regards to electric waves.Heinrich Hertz died in 1892 of Wegener&apos;s granulomatosis at the age of 36.